Mumbai, Feb 13: Strides Pharma Science Limited (Strides) on Wednesday announced that its step-down whollyowned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Triamcinolone Acetonide Cream USP, 0.025 pc, 0.1 pc and 0.5 pc. from the United States Food & Drug Administration (US FDA).
The product is a generic version of Triamcinolone Acetonide Cream of Mylan Pharmaceuticals Inc. According to IQVIA MAT data, the US market for Triamcinolone Acetonide Cream USP, 0.025 pc, 0.1 pc and 0.5 pc. is approximately USD 55 Mn.
The product will be manufactured at flagship facility in Bangalore and will be marketed by Strides Pharma Inc. in the US market.
The company has 86 cumulative ANDA filings with USFDA of which 56 ANDAs have been approved including 12 approvals received in FY 19.
Triamcinolone Acetonide Cream is used to treat a variety of skin conditions including treatment of eczema, dermatitis, allergies, rash and helps in reducing swelling, itching, and redness that can occur in these types of conditions. (UNI)